Navigation Links
Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
Date:8/29/2012

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed but results have been inconclusive at best and at times contradictory. A University of Colorado Cancer Center study recently published in the Journal of Thoracic Oncology provides an explanation why: only in combination with high levels of a second enzyme, FPGS, does low TS predict response to pemetrexed in patients with malignant pleural mesothelioma.

"The hope is that oncologists could test a patient for TS and FPGS levels and so discover if the patient should be treated with pemetrexed or if another therapy might be more appropriate," says the paper's first author, Daniel C. Christoph, MD, PhD, medical oncologist at the West German Cancer Center, working as an international postdoctoral researcher in the lab of CU Cancer Center investigator, Fred Hirsch, MD, PhD.

Pemetrexed works by inhibiting the enzyme TS, which cancer cells need in order to replicate their DNA. So it stands to reason that tumors already low in TS would be most affected by the drug blocking the remaining TS would effectively stop the ability of cancer cells to synthesize new DNA. However, Christoph and colleagues tested 84 samples of mesothelioma in which patients had been treated with pemetrexed and found that low levels of TS only in combination with concurrently high levels of FPGS predicted patients' response to the drug.

The study also explained the mechanism by which FPGS increases the clinical effectiveness of pemetrexed:

"High levels of FPGS allow pemetrexed to stay longer inside cells, giving the drug longer to work against TS," Christoph says. Of the samples tested, patients with low TS and high FPGS had more response to pemetrexed and longer durations of survival.

According to Christoph, the current study provides the preclinical work needed to justify exploring the predictive power of TS and FPGS in mesothelioma patients. A prospective observational study of these biomarkers could lead to their wide use in predicting patients' response to pemetrexed.


'/>"/>
Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the ... in large part by the Hospital Readmission Reduction Program (HRRP), the return of a ... area for hospitals across the nation. While many providers are struggling to leverage limited ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... over 10 years of research, development and clinical trials, the founder of Chigurupati ... a patented compound of FDA approved ingredients that when infused into alcohol, protect ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection ... patient care, NWH has achieved Magnet® recognition for the second time, ... 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 ... that positive Phase 1 clinical data for Nektar,s lead ... (RCC) were presented at ASCO GU 2017.  NKTR-214 is ... T cells and Natural Killer (NK) cell abundance directly ... on these immune cells.  The results were presented by ...
(Date:2/17/2017)... 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, ... global ablation technologies market is expected to grow at a CAGR ... market is expected to grow at a CAGR of 9.5% from ... and $9.05bn in 2026. ... How this report will benefit you Read on to ...
(Date:2/17/2017)... Feb. 17, 2017 Theravance Biopharma, Inc. ... the "Company") today announced the presentation of positive ... orally administered pan-Janus kinase (JAK) inhibitor designed to ... Congress of the European Crohn,s and Colitis Organization ... further data from its completed Phase 1 study ...
Breaking Medicine Technology: